Frazier Life Sciences
1001 Page Mill Road Building 4, Suite 200B, Palo Alto, CA, 94304, United States
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Slate Medicines | Aug 2026Led | $245 MOther Equity | |
Crystalys Therapeutics | Jul 2026Led | $130 MSeries B | |
RQ Bio | Jun 2026Led | $115 MSeries A | |
cAMPfield Therapeutics | May 2026Participated | $180 MSeries A | |
Sidewinder Therapeutics | Apr 2026Led | $137 MSeries B | |
Immutrin | Mar 2026Led | $87 MSeries A | |
Vima Therapeutics | Mar 2026Participated | $100 MSeries A | |
Angitia Biopharmaceuticals | Feb 2026Led | $130 MSeries D | |
AirNexis Therapeutics | Jan 2026Led | $200 MSeries A | |
Diagonal Therapeutics | Jan 2026Participated | $125 MSeries B | |
Parabilis Medicines | Jan 2026Participated | $305 MSeries F | |
Iolyx Therapeutics | Dec 2025Led | $15 MSeries B | |
Slate Medicines | Aug 2026Led | $245 MOther Equity | |
Crystalys Therapeutics | Jul 2026Led | $130 MSeries B | |
RQ Bio | Jun 2026Led | $115 MSeries A | |
cAMPfield Therapeutics | May 2026Participated | $180 MSeries A | |
Sidewinder Therapeutics | Apr 2026Led | $137 MSeries B | |
Immutrin | Mar 2026Led | $87 MSeries A | |
Vima Therapeutics | Mar 2026Participated | $100 MSeries A | |
Angitia Biopharmaceuticals | Feb 2026Led | $130 MSeries D | |
AirNexis Therapeutics | Jan 2026Led | $200 MSeries A | |
Diagonal Therapeutics | Jan 2026Participated | $125 MSeries B | |
Parabilis Medicines | Jan 2026Participated | $305 MSeries F | |
Iolyx Therapeutics | Dec 2025Led | $15 MSeries B |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 1 |
| Series A | 9 | 5 |
| Series B | 4 | 8 |
| Series C+ | 5 | 8 |
| Other Equity | 1 | 3 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jan '22 | 1 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 1 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 1 |
| Oct '22 | 1 |
| Nov '22 | 1 |
| Dec '22 | 2 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 1 |
| Jun '23 | 1 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 1 |
| Jan '24 | 1 |
| Feb '24 | 0 |
| Mar '24 | 1 |
| Apr '24 | 2 |
| May '24 | 2 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 2 |
| Sep '24 | 0 |
| Oct '24 | 2 |
| Nov '24 | 1 |
| Dec '24 | 1 |
| Jan '25 | 1 |
| Feb '25 | 0 |
| Mar '25 | 2 |
| Apr '25 | 1 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 3 |
| Nov '25 | 2 |
| Dec '25 | 1 |
| Jan '26 | 3 |
| Feb '26 | 1 |
| Mar '26 | 2 |
| Apr '26 | 1 |
| May '26 | 1 |
| Jun '26 | 1 |
| Jul '26 | 1 |
| Aug '26 | 1 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 44 |
| Space & Frontier Tech | 2 |
| Manufacturing | 1 |
| AI & Machine Learning | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 2 |
| $25M-$50M | 1 |
| $50M-$100M | 11 |
| $100M-$250M | 28 |
| $250M-$500M | 2 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 5 of 5 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 34 |
| Europe | 7 |
| China | 1 |
| Canada | 1 |
| V5t 1m4 | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| RA Capital Management | 15 |
| Deep Track Capital | 11 |
| OrbiMed | 10 |
| Novo Holdings | 7 |
| Wellington Management | 7 |
| BVF Partners | 6 |
| Janus Henderson Investors | 6 |
| Lightspeed Venture Partners | 6 |
| Longitude Capital | 6 |
| Nextech Invest | 6 |
| Venrock | 6 |
| Cormorant Asset Management | 5 |
| Logos Capital | 5 |
| Samsara BioCapital | 5 |
| Alexandria Venture Investments | 4 |
| Atlas Venture | 4 |
| EcoR1 Capital | 4 |
| Forbion | 4 |
| Marshall Wace | 4 |
| venBio Partners | 4 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 19 | 43% |
| Participating | 25 | 57% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 9 | 47% |
| Co-led | 10 | 53% |
Team
Vice President
General Partner
Co founder & CEO
General Partner
Venture Partner